Session 4: HIV Prevention and Cure

Clinical Case: Potential Challenges of Drug Interactions of Long-Acting Agents

Catia Marzolini, PharmD, PhD

University of Liverpool/University Hospital Basel Basel Switzerland





Global HIV Clinical Forum 2020 #HIVCF #GLOHCF Enduring materials available at www.AcademicMedicalEducation.com

Clinical case: Potential challenges of drug interactions of long-acting agents

Catia Marzolini

University Hospital & University of Basel University of Liverpool









Global HIV Clinical Forum 2020

- Adrian 29 year-old MSM
- Multiple male sexual partners per month, condom use inconsistent
- BMI: 28 kg/m²
- Currently on PrEP with TDF/FTC
- Last control: HIV antigen/antibody negative, HBsAg negative,
- eGFR 90 mL/min/1.73 m²
- Chemsex (ecstasy, methamphetamine)
- Medications: occasionally antacids, St John's Wort (mild depression)

Case presentation

- Adrian heard that Cabotegravir is more efficient than TDF/FTC to prevent HIV infection
- Would Cabotegravir PrEP be suitable for Adrian?

Press release on May 2020

Global HIV Prevention Study Ends Early After Injectable Cabotegravir Shows High Efficacy





Study population: MSM and transgender women at high risk for HIV acquisition (n = 4570).

Randomized, double-blind study comparing:


- cabotegravir 600 mg im every 8 weeks
- TDF/FTC 245/300 mg oral once daily

Results:

- overall 50 incident HIV infections (incidence 0.79%)
- 38 infections with TDF/FTC (incidence 1.21%)
- 12 infections with cabotegravir (incidence 0.38%)


Evaluation of weight gain in HPTN077

Population (n = 177): median age: 31.5 years; 66% female; median BMI: 26.6 kg/m² (IQR: 23.4-32.7)



No differences in weight gain between cabotegravir and placebo arms. No differences among ethnic groups or sex.

Obesity and drug delivery in the muscle



- Cabotegravir injection performed in gluteal muscle.
- Muscle has rich vascular supply favoring drug absorption.
- Subcutaneous adipose tissue has less vascular supply which may result in less drug absorption.
- Injection technique is critical to ensure drug is not deposited in subcutaneous adipose tissue.
- Cabenuva label indicates that longer needle lengths may be required for patients with higher BMI to ensure that drug is delivered im.


Cabotegravir and rilpivirine plasma levels

Median (5th and 95th percentile) plasma CAB and RPV trough levels over time

Oral lead-in: CAB/RPV 30/25 mg QD for 4 weeks

Initial im dose: CAB/RPV 600/900 mg im at week 4

Maintenance im dose: CAB/RPV 400/600 mg im from week 8 and every 4 weeks thereafter




Patel P et al. ID week 2019

Cabotegravir and rilpivirine plasma levels in obese vs non-obese

Median (5th and 95th percentile) plasma CAB and RPV trough levels over time

In FLAIR and ATLAS: 17% participants had BMI \ge 30 kg/m² 13% were male with BMI \ge 30 kg/m² 27% were female with BMI \ge 30 kg/m²




- 4 weeks following the first injection, median cabotegravir levels were 46% lower in obese vs non-obese => slower absorption resulting in initial lower trough that increases over time with no difference at week 32
- RPV is not affected by BMI

Ę

* in a low dose rectal challenge model, plasma CAB concentrations > 3x PA-IC90 provided 100% protective efficacy, 1-3 x PA-IC90 provided 97% protective efficacy

Cabotegravir and rilpivirine plasma levels in female vs men

Median (5th and 95th percentile) plasma CAB and RPV trough levels over time



- 4 weeks following the first injection, median cabotegravir levels were 40% lower in female vs male
- RPV is not affected by sex
- in a low dose rectal challenge model, plasma CAB concentrations > 3x PA-IC90 provided 100% protective efficacy, 1-3 x PA-IC90 provided 97% protective efficacy
- In a vaginal challenge model, plasma CAB concentrations > 4x PA-IC90 provided 87% protective efficacy

Patel P et al. ID week 2019

Gender effect on the pharmacokinetics of oral and iv drugs

Meta analysis of existing studies (n = 64) comparing gender PK

2 1.5 1 0.5 0 t 1 / 2 С CLF VdF AUC inf

Parameter	Difference
C _{max}	↑ 20%
t _{max}	0%
AUC _{inf}	↑ 17%
CLF	↓ 11%
VdF	0%
t _{1/2}	-1%

Explained by differences in body weight and metabolism resulting in reduced first pass effect and hepatic metabolism.

Data represent ratio women/men

- Adrian 29 year-old MSM
- Multiple male sexual partners per month, condom use inconsistent
- BMI: 28 kg/m²
- Currently on PrEP with TDF/FTC
- Last control: HIV antigen/antibody negative, HBsAg negative,
- eGFR 90 mL/min/1.73 m²
- Chemsex (ecstasy, methamphetamine)
- Medications: occasionally antacids, St John's Wort (mild depression)

Cabotegravir metabolism

	Cabotegravir	Effect of Cabotegravir on UGTs, CYPs, transporters
Metabolism	UGT1A1 (minor UGT1A9)	No inhibitory or inducing effects on: CYPs UGTs
Transport	P-gp, BCRP High intestinal permeability (inhibitors unlikely to impact CAB absorption) OATP1B1/3, OAT3, MRP2, MRP3, MRP4	No clinically significant inhibitory effects on: P-gp, BCRP, MRP4, MRP2, OATP1B1/3, OCT1/2, BSEP, MATE1, MATE2K, OAT1/3
T _{1/2}	oral: 41 hours im: 5.6-11.5 weeks	


Drug-drug interactions with Chemsex

Cabotegravir does not interact with Chemsex

Drug	Metabolism	Interaction Potential	
		Cobicistat Ritonavir	BIC, CAB, DOR, DTG, RAL, MVC, RPV, NRTIs
Benzodiazepines: Midazolam, Triazolam	CYP3A4	High	Low
Benzodiazepines: Others	CYP3A4	High	Low
Cocaine	CYP3A4 (minor)	Low-moderate	Low
Ecstasy (MDMA)	CYP2D6	Limited CYP2D6 inhibition, but small PK changes could be significant due to non-linear PK.	Low
GHB	GHB dehydrogenase CYP?	Unknown. Caution due to GHB narrow therapeutic index	Low
Ketamine	СҮРЗА4	High	Low
Mephedrone	CYP2D6	Limited CYP2D6 inhibition	Low
Methamphetamine	CYP2D6	Limited CYP2D6 inhibition, but small PK changes could be significant due to non-linear PK.	Low

www.hiv-druginteractions.org

Drug-drug interactions with antacids




No chelation with im administration

Administer antacids 2 h before or 4 h after oral cabotegravir

www.hiv-druginteractions.org

Intramuscular administration characterized by flip-flop pharmacokinetics

In case of flip-flop pharmacokinetics, the rate of absorption is slower than rate of elimination ($K_{el} > K_a$)




In presence of strong inducers, AUC is decreased as elimination rate increases but $t_{1/2}$ remains constant as it is controlled by absorption rate.

Courtesy of Prof. Owen A

Drug-drug interactions with strong inducers

No Interaction Expected	Do Not Coadminister	Do Not Coadminister
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)	Cabotegravir [oral] (CAB oral)	Cabotegravir/rilpivirine [long acting] (CAB/RPV LA)
St John's Wort	St John's Wort	St John's Wort
Oral cabotegravir + rifampicin	Cabotegravir im + rifan	npicin
CAB AUC \downarrow by 59%; t _{1/2} \downarrow by 57%	CAB AUC \downarrow by 41%; t _{1/2} \leftrightarrow	CAB AUC \downarrow by 46%; t _{1/2} \leftrightarrow
CAB (n=15) -→- CAB + RIF (n=15)	A CAB 400 mg 1 x/month	B CAB 600 mg 1 x/2 month
	$\overline{\mathbb{Q}}^{2}$	$\vec{z}_{2,5}$




Ford SL et al. AAC 2017

Rajoli RKR et al. JID 2019

What about moderate inducers

Oral cabotegravir + rifabutin

CAB AUC \downarrow by 21%; Ctrough \downarrow by 26%




Cabotegravir [oral] (CAB oral)

Rifabutin

Ford SL et al. Antiviral Ther 2019

Current gap: DDI in special populations



Could DDI with moderate inducers become relevant in an obese woman in the early phase of cabotegravir injection?



Ongoing phase III study evaluating efficacy and safety of CAB LA compared to oral PrEP in women


What about strong inhibitors of UGT1A1

DDI predictions using PBPK modelling

Substrate –	CAB AUC Ratio*	CAB Cmax Ratio*	
Inhibitor/Inducer DDI Enzyme	Geometric Mean (5th-95 th percentile)	Geometric Mean (5th-95 th percentile)	
	Predicted	Predicted	
Cabotegravir –			
Atazanavir	1.11	1.02	
UGT1A1 Inhibition	(1.04, 1.20)	(1.01, 1.04)	
Cabotegravir –			
Mefenamic Acid	1.10	1.02	
UGT1A9 Inhibition	(1.04, 1.18)	(1.01, 1.03)	

Effect of UGT1A1*6 and UGT1A1*28 (reduced function) on CAB pharmacokinetics

CAB 400 mg 1 x/month




Genetic variations resulted in modest elevations of oral cabotegravir exposure (28-50% increase) and im cabotegravir exposure (16-24%).


Case presentation

• Adrian is considering undergoing gender reassignment and wonder whether cabotegravir does interact with hormones

Drug-drug interactions with hormonal contraception



Ę



- Oral contraceptive associated with lower CAB LA peak but no significant effect on other PK parameters
- Other contraceptives caused no changes in CAB-LA PK

Drug-drug interactions with hormone therapy for gender affirming

No significant pharmacokinetic interactions expected with cabotegravir


Estrogen and anti-androgen preparations for use in male to female gender reassignment therapy

		HIV drugs with no predicted effect	HIV drugs predicted to	HIV drugs predicted to
			inhibit metabolism	induce metabolism
Estrogens		CAB, DOR, RPV, MVC, BIC, DTG, RAL	ATV alone, ATV/cobi,	ATV/r, DRV/r, FPV/r, IDV/r, LPV/r,
	Charting dage	ABC, ddl, FTC, 3TC, d4T, TAF, TDF, ZDV	DRV/cobi, EVG/cobi	SQV/r, TPV/r, EFV, ETV, NVP
Estradiol oral	Starting dose	2 mg/day	1 mg/day	Increase estradiol dosage as needed
	Average dose Maximum dose	4 mg/day	2 mg/day	based on clinical effects and
		8 mg/day	4 mg/day	monitored hormone levels.
Estradiol gel	Starting dose	0.75 mg twice daily	0.5 mg twice daily	Increase estradiol dosage as needed
(preferred for >40 y	Average dose	0.75 mg three times daily	0.5 mg three times daily	based on clinical effects and
and/or smokers)	Maximum dose	1.5 mg three times daily	1 mg three times daily	monitored hormone levels.
Estradiol patch	Starting dose	25 μg/day	25 μg/day*	Increase estradiol dosage as needed
(preferred for >40 y	Average dose	50-100 µg/day	37.5-75 μg/day	based on clinical effects and
and/or smokers)	Maximum dose	150 µg/day	100 µg/day	monitored hormone levels.
Conjugated	Starting dose	1.25-2.5 mg/day	0.625-1.25 mg/day	Increase estradiol dosage as needed
estrogen†	Average dose	5 mg/day	2.5 mg/day	based on clinical effects and
estrogen	Maximum dose	10 mg/day	5 mg/day	monitored hormone levels.
Ethinylestradiol	Starting dose	No interaction expected, but not recommended due to thrombotic risks	Not recommended	Not recommended
	Average dose			
	Maximum dose			
Androgen Blockers		CAB, DOR, RPV, MVC, BIC, DTG, RAL	ATV alone, ATV/cobi, ATV/r,	EFV, ETV, NVP
		ABC, ddl, FTC, 3TC, d4T, TAF, TDF, ZDV	DRV/cobi, DRV/r, EVG/cobi,	
	Starting dose	E0 mg/day	FPV/r, IDV/r, LPV/r, SQV/r, TPV/r	
0	Average dose	50 mg/day	No interaction expected.	No interaction expected. No dose adjustment required.
Spironolactone	Maximum dose	150 mg/day	No dose adjustment required.	
		400 mg/day		
	Starting dose	2.5 mg/day	Finasteride has a large safety margin.	Increase finasteride dosage as needed
Finasteride	Average dose	2.5 mg/day	No dose adjustment required.	based on clinical effects and
	Maximum dose	5 mg day		monitored hormone levels.
Cyproterone	Starting dose	50 mg/day	25 mg/day	Increase cyproterone dosage as
acetate	Average dose	150 mg/day	75 mg/day	needed based on clinical effects and
	Maximum dose	150 mg/day	75 mg/day	monitored hormone levels.
	Starting dose	3.6 mg/month	No interaction expected. No dose adjustment required.	No interaction expected.
Goserelin	Average dose	3.6 mg/month		No dose adjustment required.
	Maximum dose	3.6 mg/month		tto dose adjustment required.
Leuprorelin acetate	Starting dose	3.75 mg/month	No interaction expected.	No interaction expected
	Average dose	3.75 mg/month		· ·
	Maximum dose	3.75 mg/month	No dose adjustment required.	No dose adjustment required.
Triptorelin	Starting dose	3.75 mg/month		
	Average dose	3.75 mg/month		No interaction expected. No dose adjustment required.
	Maximum dose	3.75 mg/month	No dose adjustment required.	
acetate	Starting dose Average dose Maximum dose Starting dose Average dose	3.75 mg/month 3.75 mg/month 3.75 mg/month 3.75 mg/month 3.75 mg/month 3.75 mg/month	· · ·	No interaction expecte No dose adjustment requ No interaction expecte

www.hiv-druginteractions.org

Feminizing hormone therapy and lower rectal tissue tenofovir diphosphate

Tenofovir-DP and endogenous nucleotide ratio in rectal tissue




- median TFVdp:dATP was 7-fold lower in rectal tissue (but not PBMC) in transgender women taking feminizing hormones
- no differences in FTCtp:dCTP in blood or rectal tissue
- no increase in rectal HIV RNA or DNA was observed
- additional studies are needed to determine the clinical implication

Cottrell ML et al. Clin Infect Dis 2019

PK study in transgender women using PrEP showed modestly lower plasma FTV exposure however FTVdp levels were not reduced in PBMC. The authors mention that there is no need to adjust PrEP.

Drug-drug interactions profiles of PrEP

n = 724 comedications



no interactioninteraction of clinical relevance

Interaction of weak clinical relevance

deleterious interaction

www.hiv-druginteractions.org

Would cabotegravir PrEP be suitable for Adrian

- No interaction with Chemsex
- No interactions with antacids (separate intake oral CAB from antacids)
- Major interaction with SJW => change antidepressant
- No interaction with gender transitioning drugs

- Cabotegravir LA and oral PrEP have a low risk for drug-drug interactions.
- Better understanding is needed with regard to cabotegravir exposureresponse relationship for prevention in both men and female.
- Better understanding of cabotegravir PK is needed in special populations.

Acknowledgements

- University Hospital Basel

Manuel Battegay

Felix Stader



David Back

Saye Khoo

Marco Siccardi

HIV Drug Interactions

Liverpool website team & editorial board

Saye Khoo

Liverpool - Website Team





David Back Liverpool - Chair

Sara Gibbons





Catia Marzolini Basel - Website Team & Swiss Mas Chaponda Liverpool – BHIVA representative

David Burger Nijmegen – EACS representative







Jonathan Schapiro Tel Aviv - Glasgow

Charles Flexner Baltimore

Mohammed Lamorde Infectious Diseases Institute Kampala



Katie Moss Liverpool





Marta Boffito















Justin Chiong

Jasmine Martin Liverpool

Glasgow

Alison Boyle

